Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The interaction between the fibrin E1 fragment and vascular endothelial (VE)-cadherin is a key molecular event implicated in angiogenesis, inflammation, and vascular integrity. VE-cadherin is an endothelium-specific adhesion protein located at intercellular junctions of endothelial cells. The binding site for the fibrin E1 fragment on VE-cadherin has been mapped to its extracellular domains EC3 & EC4. On the fibrin side, the E1 fragment corresponds to a region within fibrin(ogen) that includes both βN-domains. Specific residues within these βN-domains—particularly His16 and Arg17—are essential for binding to VE-cadherin. This interaction triggers capillary-like structure formation by endothelial cells and modulates inflammatory responses by affecting endothelial permeability.
Disruption or modulation of Fibrin E1 - VE-cadherin binding
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fibrin E1 Fragment Binding Site on VE-cadherin.